Detalhe da pesquisa
1.
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
N Engl J Med
; 389(4): 309-321, 2023 Jul 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37494485
2.
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Alzheimers Dement
; 20(5): 3406-3415, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38567735
3.
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
J Neurol Neurosurg Psychiatry
; 87(5): 468-75, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26111826
4.
Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
Epilepsia
; 57(2): 210-21, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26666500
5.
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
BMC Neurol
; 14: 21, 2014 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24475777
6.
Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.
Epilepsia
; 54(1): 89-97, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22813235
7.
Advancing combination therapy for Alzheimer's disease.
Alzheimers Dement (N Y)
; 6(1): e12073, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33043108
8.
Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
J Neurol
; 262(12): 2627-34, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26338810
9.
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
Neurology
; 84(8): 784-93, 2015 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-25632085
10.
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
Neurology
; 84(9): 872-9, 2015 Mar 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25636714
11.
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Neurology
; 84(15): 1582-91, 2015 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795646
12.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Neurology
; 85(1): 29-39, 2015 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26024899
13.
The prototypic mineralocorticoid receptor agonist aldosterone influences neurogenesis in the dentate gyrus of the adrenalectomized rat.
Brain Res
; 947(2): 290-3, 2002 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-12176172
14.
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
J Neurol
; 261(2): 267-76, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24221641
15.
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.
Mult Scler Relat Disord
; 3(3): 341-9, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25876471
16.
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings.
Mult Scler Relat Disord
; 3(4): 494-504, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25877062
17.
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Neurol
; 13(6): 545-56, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24685276
18.
Brivaracetam (UCB 34714).
Neurotherapeutics
; 4(1): 84-7, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17199019